LETTER TO THE EDITOR

The equine Hendra virus vaccine remains a highly effective preventative measure against infection in horses and humans: ‘The imperative to develop a human vaccine for the Hendra virus in Australia’

Alison J. Peel, BSc (Vet), BVSc, MSc, PhD1, Hume E. Field, BVSc, MSc, PhD, MACVS2, Peter A. Reid, BVSc (Hons), BAgSc3, Raina K. Plowright, BVSc, MSc (Epidemiology), PhD (Ecology)4, Christopher C. Broder, BSc, MSc, PhD5, Lee F. Skerratt, BAnSc, BVSc, PhD, MANZCVSc6, David T. S. Hayman, BVM&S, MSc, Dip. ECZM, PhD7, Olivier Restif, MEng, MSc, PhD8, Melanie Taylor, BSc (Hons) Psychology, PhD9, Gerardo Martin, BVSc, MSc9, Gary Crameri, BSc10, Ina Smith, BASc (Hons), PhD10, Michelle Baker, PhD10, Glenn A. Marsh, BASc (Hons), PhD10, Jennifer Barr, BSc (Hons)10, Andrew C. Breed, BSc, BVMS, MSc, PhD11, James L. N. Wood, BSc, BVetMed, MSc, PhD, Dip. ECVPH8, Navneet Dhand, BVSc&AH, MVSc, MANZCVS (Vet epidemiology), PhD, GradCert (Higher Education)12, Jenny-Ann Toribio, BVSc, MANZCVSc, MEd (Higher Education), PhD12, Andrew A. Cunningham, BVMS, PhD, MRCVS, Dip. ECZM (Wildlife Population Health)13, Ian Fulton, BVSc, MSc, FACVS (Specialist in Equine Surgery)14, Wayne L. Bryden, BRurSc, MRurSc, Dip Ed, PhD, FIAAST, FNSA, FASAP15, Cristy Secombe, BSc, BVMs, MACVS, MVSc (Hons), Dip. ACVIM16 and Lin-Fa Wang, BSc, PhD, FTSE17

1Environmental Futures Research Institute, Griffith University, Nathan, QLD, Australia; 2EcoHealth Alliance, New York, NY, USA; 3Australian Veterinary Association Representative, Queensland Government Hendra virus Interagency Technical Working Group, Brisbane, Australia; 4Department of Microbiology & Immunology, Montana State University, Bozeman, MT, USA; 5Department of Microbiology & Immunology, Uniformed Services University, Bethesda, MD, USA; 6One Health Research Group, College of Public Health, Medical and Veterinary Sciences, James Cook University, Townsville, QLD, Australia; 7mEpiLab, Infectious Disease Research Centre, Hopkirk Research Institute, Massey University, Palmerston North, New Zealand; 8Department of Veterinary Medicine, University of Cambridge, Cambridge, Cambridge, United Kingdom; 9Department of Psychology, Macquarie University, Sydney, NSW, Australia; 10CSIRO Australian Animal Health Laboratory, Geelong, VIC, Australia; 11Department of Epidemiology, University of Cambridge, Cambridge, Cambridge, United Kingdom; 12Department of Veterinary Science, The University of Sydney, Sydney, NSW, Australia; 13Institute of Zoology, Zoological Society of London, NW1 4RY London, United Kingdom; 14President Equine Veterinarians Australia, St Leonards, NSW, Australia; 15Equine Research Unit, School of Agriculture and Food Sciences, University of Queensland, Gatton, QLD, Australia; 16School of Veterinary and Life Sciences, Murdoch University, Murdoch, WA, Australia; 17Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore

The Commentary to which this Letter to the Editor responds can be found at: http://dx.doi.org/10.3402/iee.v5.29619. A rebuttal to this Letter to the Editor can be found at: http://dx.doi.org/10.3402/iee.v6.31659

To the Editor

In their commentary article, ‘The imperative to develop a human vaccine for the Hendra virus in Australia’, Zahoor and Mudie (1) argue the case for a human Hendra virus (HeV) vaccine. The statements supporting their arguments are incorrect and have the potential to cause
confusion and ultimately undermine confidence in current evidence-based risk management strategies, thereby placing equine and human lives at risk.

The central argument in Zahoor and Mudie (1) is that HeV is ‘rapidly mutating’, with consequent loss of efficacy of the equine HeV vaccine, changing clinical syndromes in humans, and infection in new animal species. There is no scientific basis to their central argument. Zahoor and Mudie (1) offer no citations to support their statements regarding the mutation rate of HeV. Indeed, primary research indicates the HeV genome has minimal variability (less than 1% at both the nucleotide and amino acid levels) in both flying-foxes and horses and is highly stable (the same variant has been detected at disparate locations at the same time, and over periods of at least 12 years) (2, 3).

There is no evidence that the equine HeV vaccine is becoming less effective. Continuing equine HeV cases do not reflect loss of vaccine efficacy as stated by Zahoor and Mudie (1), but rather a failure of some horse owners to vaccinate their horses. There have been no HeV cases in vaccinated horses. The efficacy and safety of the recombinant equine vaccine has been clearly demonstrated (4–6), and both government and industry animal health authorities strongly recommend its use as ‘the single most effective way of reducing the risk of Hendra virus infection in horses’ (7).

There is no evidence that the nature of human HeV infection is changing. The seven recognised human cases have shared clinical features but are insufficient in number to determine changes over time (8–13).

There is no evidence that recently reported canine cases indicate that HeV is ‘seeking new co-hosts’. The wide host range of HeV in experimental studies is well established (14, 15). The two observed cases of natural HeV infection in dogs most likely resulted from exposure to infected horses, or contaminated material from these horses, and their detection may reflect increased surveillance of canines on infected equine premises (16).

There is no evidence that HeV infections ‘are emerging in locations far beyond bats’ typical migratory boundaries’. Several recent publications demonstrate that the spatial occurrence of equine HeV cases reflects the distribution of black and spectacled flying-foxes (17–19).

In conclusion, we express no objection to the development of a human vaccine against HeV; however, we are emphatic that Zahoor and Mudie (1) are unjustified in using viral evolution, vaccine inefficiency, and changing clinical syndromes as motivations. There are no data to support their case.

Conflict of interest and funding
Dr. Broder reports a grant (CRADA) from Zoetis, Inc., outside the submitted work. In addition, Dr. Broder is a coinventor on U.S. Patent No. 8,865,171 and 9,045,532, with royalties paid by Zoetis, Inc., and Australian Patent No. 2005327194 Patent assignees are the United States of America as represented by the Department of Health and Human Services (Washington DC) and the Henry M. Jackson Foundation (Bethesda, MD).

Dr. Restif reports grants from The Royal Society, during the conduct of the study; he further discloses that he is the sponsor of a Junior Research Fellowship supported by the Axa Research Fund.

Dr. Dhand has communicated with Zoetis for submitting a joint ARC linkage project but this submission did not materialize.

Dr. Secombe is a core executive member of Equine Veterinarians Australia.

References

1. Zahoor BA, Mudie LI. The imperative to develop a human vaccine for the Hendra virus in Australia. Infect Ecol Epidemiol 2015; 5: 29619. doi: http://dx.doi.org/10.3402/iee.v5.29619


